Advantages of laserphyrin compared with photofrin in photodynamic therapy for bile duct carcinoma

Abstract

Background The aim of this study was to compare the effects of laserphyrin-PDT

Synergic effect of photodynamic therapy using talaporfin sodium with conventional anticancer chemotherapy for the treatment of bile duct carcinoma

“…36,37 Previous our studies using cultured cells showed that the main effect of PDT is apoptosis, evidenced by assays that measured either DNA fragmentation or chromatin condensation. 17,18 PDT induced NOZ cell death by apoptosis, detected in the Hoechst 33342-stained sections, in a light dose-dependent manner. Based on this preliminary study, the photosensitizer dose and light dose were already determined, which was applied in the present study.…”

“…The estimated talaporfin sodium dose was 20 μg/ml as determined by our preliminary study. 18 The administered solution was incubated at 37°C for 3 hours, later decantated and then washed three times in PBS. To induce LD 50 PDT conditions, a laser power of 12 J/cm 2 was chosen to irradiate the NOZ cells.…”

“…The laser was irradiated for 1 minute. Apoptotic induction of the NOZ cells in each group was investigated following the cell treatment under the LD 50 conditions as determined in our preliminary study 18 . Each sample was again incubated overnight at 37°C, and 20 μl of MTS solution (CellTiter96 ® AQueous One Solution Cell Proliferation Assay Promega Co. Madison, WI, USA) was added.…”

“…The adequate administrative dose of talaporfin sodium was 5 mg/kg based on our preliminary study. 18 …”

“…15,16 Based on the demonstrated clinical effectiveness and the photosensitivity principles, a study that compared L-PDT and P-PDT for the treatment of human biliary cancer cells was examined. 17,18 The Page 4 study demonstrated that L-PDT was a more powerful and effective anticancer treatment, had a higher percent of tumor necrosis and apoptosis, a lower cancer cell proliferation activity and a higher anti-angiogenic activity. Based on these results, a clinical trial evaluating the L-PDT treatment in BDC patients has begun (not published in English).…”